Drugs / Nitazoxanide
Nitazoxanide
also known as
NTZ · NTZ (nitazoxanide) · Alina · Alinia · G1090N · Netazox · Nitazoxanida · NSC-697855 · +5 more
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | ALINIA | — | 2004-07-21 – 2005-06-16 | fda.gov ↗ |
| Approved | US (FDA) | ALINIA | — | 2002-11-22 | fda.gov ↗ |
Trials 77 · started per year
today
US approved 2002
1
1
1
4
5
4
1
1
4
2
1
2
2
2
1
5
1
19
6
5
2
1
3
2
1995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07110441 | Aug → Dec 2025 | liver disorder | Genfit | Completed | No outcome recorded |
| Phase 1 | NCT05368935 | Apr → Sep 2022 | impaired renal function disease | Genfit | Completed | No outcome recorded |
| Phase 1 | NCT05116826 | Nov 2021 → Apr 2022 | liver disorder | Genfit | Completed | No outcome recorded |
| Phase 1 | NCT01074203 | Feb 2009 → Jan 2011 | hepatitis C virus infection | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00002444 | Oct 1995 → Feb 1996 | HIV infectious disease | Unimed Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/24 trials · 1 missed | ||||||
| Phase 1/2 | NCT05453916 | Jul 2022 → Jul 2024 | irritable bowel syndrome | Sadat City University | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04746183 | Jul 2020 → Mar 2027 expected | COVID-19 | University of Liverpool | Recruiting | Missed primary |
| Phase 1/2 | NCT01185028 | Aug 2010 → Oct 2011 | HIV infectious disease, chronic hepatitis C virus infection | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1/2 | NCT00055107 | ? → May 2006 | HIV infectious disease, cryptosporidiosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 226 trials · 7 missed | ||||||
| Phase 2 | NCT07756255 | Aug 2026 → Aug 2028 expected | attention deficit-hyperactivity disorder | University of Calgary | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06010992 | Oct 2023 → Oct 2024 | type 2 diabetes mellitus | Tanta University | Unknown | Missed primary |
| Phase 2 | NCT04918927 | Oct 2021 → Mar 2023 | COVID-19 | Coordinación de Investigación en Salud, Mexico | Completed | No outcome recorded |
| Phase 2 | NCT05041907 | Sep 2021 → Jan 2027 expected | COVID-19 | University of Oxford | Recruiting | Mixed |
| Phase 2 | NCT04459286 | Oct 2020 → May 2021 | COVID-19 | Obafemi Awolowo University | Terminated | Missed primary |
| Phase 2 | NCT04532931 | Sep 2020 → Aug 2021 | COVID-19 | Shin Poong Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04552483 | Jun → Aug 2020 | COVID-19 | Federal University of Rio de Janeiro | Completed | No outcome recorded |
| Phase 2 | NCT04435314 | Jun → Aug 2020 | COVID-19 | Azidus Brasil | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT04561219 | Apr → Oct 2020 | COVID-19, viral pneumonia | Federal University of Rio de Janeiro | Completed | Missed primary |
| Phase 2 | NCT04768530 | Jul 2019 → Apr 2020 | periodontitis | Maha Talaab | Completed | No outcome recorded |
| Phase 2 | NCT03656068 | Dec 2018 → Nov 2020 | cirrhosis of liver, fibrotic liver disease, metabolic dysfunction-associated steatohepatitis | Pinnacle Clinical Research, PLLC | Completed | No outcome recorded |
| Phase 2 | NCT03395405 | Oct 2018 → Aug 2021 | norovirus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 2 | NCT02684240 | Feb 2016 → Apr 2018 | tuberculosis | Weill Medical College of Cornell University | Completed | Missed primary |
| Phase 2 | NCT02334163 | Dec 2014 → Feb 2015 | hepatic encephalopathy | Ain Shams University | Unknown | No outcome recorded |
| Phase 2 | NCT02057757 | Feb 2014 → May 2017 | lung disorder | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 2 | NCT01529073 | Feb 2012 → Feb 2015 | HIV infectious disease, hepatitis C virus infection | Juan Macías | Unknown | Missed primary |
| Phase 2 | NCT02366884 | Jul 2011 → Dec 2022 | neoplasm | Dr. Frank Arguello Cancer Clinic | Unknown | No outcome recorded |
| Phase 2 | NCT00991289 | Jan → Nov 2010 | HIV infectious disease, hepatitis C virus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00637923 | Mar 2008 → Apr 2010 | chronic hepatitis C virus infection | Romark Laboratories L.C. | Completed | No outcome recorded |
| Phase 2 | NCT00763568 | Aug 2006 → Sep 2008 | chronic hepatitis C virus infection | Romark Laboratories L.C. | Completed | No outcome recorded |
| Phase 2 | NCT00418054 | Dec 2005 → Jul 2006 | chronic hepatitis C virus infection | Romark Laboratories L.C. | Completed | No outcome recorded |
| Phase 2 | NCT01328925 | Dec 2005 → Jun 2006 | Rotavirus infection | Romark Laboratories L.C. | Completed | No outcome recorded |
| Phase 2 | NCT00130390 | Aug 2005 → Dec 2007 | Crohn disease | Romark Laboratories L.C. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00418639 | Feb 2005 → ? | chronic hepatitis C virus infection | Romark Laboratories L.C. | Completed | No outcome recorded |
| Phase 2 | NCT00417872 | Jan 2004 → Sep 2005 | Clostridium difficile colitis | Romark Laboratories L.C. | Completed | No outcome recorded |
| Phase 2 | NCT00001081 | ? → Sep 1998 | HIV infectious disease, cryptosporidiosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/312 trials · 2 missed | ||||||
| Phase 2/3 | NCT04920838 | Apr 2021 → Aug 2023 | COVID-19 | ANRS, Emerging Infectious Diseases | Unknown | No outcome recorded |
| Phase 2/3 | NCT04959786 | Apr 2021 → Nov 2022 | pneumonia | Mansoura University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04523090 | Aug 2020 → Dec 2021 | COVID-19 | University of Cape Town | Terminated | No outcome recorded |
| Phase 2/3 | NCT04441398 | Jul → Sep 2020 | COVID-19 | Azidus Brasil | Withdrawn | No outcome recorded Stop: Business |
| Phase 2/3 | NCT04463264 | Jun → Nov 2020 | COVID-19 | Laboratorios Roemmers S.A.I.C.F. | Unknown | No outcome recorded |
| Phase 2/3 | NCT04361318 | May → Oct 2020 | COVID-19 | Tanta University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04360356 | May → Oct 2020 | COVID-19 | Tanta University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03268902 | Sep 2017 → Feb 2020 | intestinal infectious disease, nutritional deficiency disease | Haydom Lutheran Hospital | Completed | Missed primary |
| Phase 2/3 | NCT02464124 | Jan 2016 → Dec 2017 | hepatic encephalopathy | Tanta University | Unknown | No outcome recorded |
| Phase 2/3 | NCT01276756 | Dec 2010 → Nov 2012 | chronic hepatitis C virus infection | Cairo University | Completed | Missed primary |
| Phase 2/3 | NCT01197157 | Sep 2010 → Apr 2014 | chronic hepatitis C virus infection | National Liver Institute, Egypt | Completed | No outcome recorded |
| Phase 2/3 | NCT00421434 | Jun 2006 → Sep 2008 | chronic hepatitis C virus infection | Romark Laboratories L.C. | Completed | No outcome recorded |
| Phase 317 trials · 1 met primary | ||||||
| Phase 3 | NCT06600711 | Dec 2026 → Dec 2028 expected | cryptosporidiosis | Johns Hopkins Bloomberg School of Public Health | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06817096 | Feb 2025 → Dec 2026 expected | COVID-19, influenza | Azidus Brasil | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05157243 | Aug 2024 → May 2025 | COVID-19 | Romark Laboratories L.C. | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT05480878 | Dec 2022 → Mar 2023 | rheumatoid arthritis | Tanta University | Completed | No outcome recorded |
| Phase 3 | NCT04423861 | Jun 2022 → Mar 2023 | COVID-19 | Azidus Brasil | Unknown | No outcome recorded |
| Phase 3 | NCT04415983 | Jun 2020 → Oct 2030 expected | Helicobacter pylori infectious disease | Tanta University | Recruiting | No outcome recorded |
| Phase 3 | NCT04382846 | May 2020 → Dec 2030 expected | COVID-19 | Tanta University | Recruiting | No outcome recorded |
| Phase 3 | NCT04161053 | Nov 2018 → Nov 2028 expected | hepatic encephalopathy | Tanta University | Recruiting | No outcome recorded |
| Phase 3 | NCT03491995 | Apr 2018 → Apr 2023 | Helicobacter pylori infectious disease | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT02422706 | Jan 2015 → Dec 2018 | gastritis | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT02621359 | Jan 2015 → Dec 2022 | dyspepsia | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT00384527 | Dec 2006 → Oct 2007 | Clostridium infectious disease | Romark Laboratories L.C. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01326338 | Mar 2005 → May 2006 | diarrheal disease | Romark Laboratories L.C. | Completed | Met primary |
| Phase 3 | NCT00366236 | Feb 2004 → Nov 2005 | amoebiasis due to Entamoeba histolytica | Romark Laboratories L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00366730 | Feb 2004 → Nov 2005 | amoebiasis due to Entamoeba histolytica | Romark Laboratories L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00304356 | Jan 2004 → Jan 2007 | Clostridium difficile colitis | Daniel M. Musher MD | Completed | No outcome recorded |
| Phase 3 | NCT00004986 | Feb 2000 → ? | HIV infectious disease, cryptosporidiosis | Romark Laboratories L.C. | Terminated | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT06050824 | Jul 2022 → Jul 2023 | Helicobacter pylori infectious disease | Helwan University | Completed | No outcome recorded |
| Phase 4 | NCT05184491 | Oct 2021 → Feb 2022 | Helicobacter pylori infectious disease | National Liver Institute, Egypt | Unknown | No outcome recorded |
| Phase 4 | NCT04788407 | Dec 2020 → Apr 2022 | COVID-19 | Fundación Huésped | Unknown | No outcome recorded |
| Phase 4 | NCT04498936 | Jul → Oct 2020 | COVID-19 | Assiut University | Completed | No outcome recorded |
| Phase 4 | NCT04406246 | May → Dec 2020 | COVID-19 | Materno-Perinatal Hospital of the State of Mexico | Completed | No outcome recorded |
| Phase 4 | NCT04341493 | Apr → Aug 2020 | COVID-19 | Hugo Mendieta Zeron | Terminated | No outcome recorded |
| Phase 4 | NCT04039412 | Jun → Dec 2018 | Helicobacter pylori infectious disease | Ayman Magd Eldin Mohammad Sadek | Completed | No outcome recorded |
| Phase 4 | NCT01770483 | Jul 2011 → Mar 2013 | chronic hepatitis C virus infection, type 2 diabetes mellitus | Services Institute of Medical Sciences, Pakistan | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT07086937 | Jan → Jun 2025 | Helicobacter pylori infectious disease | Muhammad Aamir Latif | Completed | No outcome recorded |
| — | NCT05648422 | Jan 2023 → Jan 2025 | protein-energy malnutrition, spastic cerebral palsy | Anahuac University | Unknown | No outcome recorded |
| — | NCT05680792 | Sep 2020 → Jan 2023 | — | Obafemi Awolowo University | Completed | No outcome recorded |
| — | NCT04348409 | May → Dec 2020 | COVID-19 | Azidus Brasil | Completed | No outcome recorded |
| — | NCT00002158 | — | HIV infectious disease, cryptosporidiosis | Romark Laboratories L.C. | Unknown | No outcome recorded |
| Comparator or background therapy34 trials | ||||||
| Phase 1/2 | NCT07808450 Comparator | Sep 2026 → Sep 2027 expected | infectious peritonitis | Tanta University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT03441893 Comparator | Jan 2015 → Jul 2025 | helminthiasis, protozoa infectious disease, ulcerative colitis | Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan | Unknown | No outcome recorded |
| Phase 2 | NCT06993974 Comparator | May 2025 → Aug 2026 overdue | ulcerative colitis | Alexandria University | Recruiting | No outcome recorded |
| Phase 2 | NCT04563208 Comparator | Dec 2020 → Feb 2022 | COVID-19 | University of Witwatersrand, South Africa | Completed | No outcome recorded |
| Phase 2 | NCT04561063 Comparator | Dec 2020 → Feb 2022 | COVID-19 | University of Witwatersrand, South Africa | Completed | No outcome recorded |
| Phase 2 | NCT04605588 Comparator | Dec 2020 → Jan 2021 | COVID-19 | Rutgers, The State University of New Jersey | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03905655 Comparator | Oct 2019 → Mar 2021 | chronic hepatitis B virus infection | Romark Laboratories L.C. | Completed | No outcome recorded |
| Phase 2 | NCT02452905 Comparator | Dec 2016 → Oct 2017 | bronchiolitis | Telethon Kids Institute | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT01056380 Comparator | Jan → Dec 2010 | influenza | Romark Laboratories L.C. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00495391 Comparator | Jul 2007 → Feb 2010 | chronic hepatitis C virus infection | Romark Laboratories L.C. | Completed | No outcome recorded |
| Phase 2/3 | NCT07820046 Comparator | Jan 2027 → Jan 2028 expected | ulcerative colitis | Tanta University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05897034 Comparator | Jun 2023 → Jun 2024 overdue | bacterial sexually transmitted disease | Tanta University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT04729491 Comparator | Jun → Sep 2020 | COVID-19 | Corpometria Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT02165813 Comparator | Nov 2014 → Apr 2021 | gastroenteritis | Telethon Kids Institute | Terminated | No outcome recorded Stop: Business |
| Phase 2/3 | NCT01227421 Comparator | Dec 2010 → Apr 2011 | influenza | Romark Laboratories L.C. | Completed | No outcome recorded |
| Phase 2/3 | NCT00302640 Comparator | Feb → Sep 2005 | Rotavirus infection, adenoviridae infectious disease, norovirus infectious disease | Romark Laboratories L.C. | Completed | No outcome recorded |
| Phase 3 | NCT05157269 Comparator | Aug 2024 → Mar 2025 | COVID-19 | Romark Laboratories L.C. | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT05894954 Background | Jul 2023 → Oct 2025 | cognitive impairment with or without cerebellar ataxia, dementia | Alzheimer's Prevention and Reversal Project, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT06049901 Comparator | Mar 2023 → Mar 2025 | colorectal cancer | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT06101420 Background | Jan 2022 → Jun 2023 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT04746937 Comparator | Mar 2021 → Mar 2022 | infectious peritonitis | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT04392427 Comparator | Oct 2020 → May 2022 | COVID-19 | Mansoura University | Unknown | No outcome recorded |
| Phase 3 | NCT04489381 Comparator | Aug 2020 → Jan 2021 | enterovirus infectious disease, viral respiratory tract infection | Romark Laboratories L.C. | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT04486313 Comparator | Aug 2020 → Feb 2021 | COVID-19 | Romark Laboratories L.C. | Completed | No outcome recorded |
| Phase 3 | NCT04359680 Comparator | May 2020 → Apr 2021 | COVID-19, viral respiratory tract infection | Romark Laboratories L.C. | Completed | No outcome recorded |
| Phase 3 | NCT04343248 Comparator | May 2020 → Feb 2021 | COVID-19, viral respiratory tract infection | Romark Laboratories L.C. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03605862 Comparator | Sep 2018 → Feb 2019 | common cold, enterovirus infectious disease | Romark Laboratories L.C. | Completed | No outcome recorded |
| Phase 3 | NCT03336619 Comparator | Jan 2018 → Apr 2019 | influenza | Romark Laboratories L.C. | Completed | No outcome recorded |
| Phase 3 | NCT02612922 Comparator | Dec 2015 → Sep 2016 | influenza | Romark Laboratories L.C. | Completed | No outcome recorded |
| Phase 3 | NCT01610245 Comparator | Mar 2013 → Mar 2015 | influenza | Romark Laboratories L.C. | Completed | No outcome recorded |
| Phase 4 | NCT06827756 Comparator | Mar → Dec 2021 | cirrhosis of liver, infectious peritonitis | Tanta University | Completed | No outcome recorded |
| Phase 4 | NCT01641341 Comparator | Nov 2010 → Mar 2012 | irritable bowel syndrome | American Academy of Family Physicians | Completed | No outcome recorded |
| — | NCT01135628 Comparator | Aug 2010 → May 2014 | cirrhosis of liver, hepatic encephalopathy | National Institute of Medical Sciences and Nutrition Salvador Zubiran | Completed | No outcome recorded |
| — | NCT00683982 Comparator | Aug 2007 → May 2008 | Rotavirus infection, diarrheal disease | Centro Pediatrico Albina de Patino | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2026-03-09 | Genfit | Regulatory GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF genfit.com ↗
GENFIT (Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that the U.S. Food and Drug Administration (FDA) has granted ODD to NTZ (nitazoxanide), its investigational small-molecule drug candidate developed as a new formulation for the treatment of Acute-on-Chronic Liver Failure (ACLF). |
| 2026-01-06 | Genfit | Results GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N genfit.com ↗
today announced that G1090N – a small molecule and the Company’s lead investigational drug candidate for Acute-On-Chronic Liver Failure (ACLF) – demonstrated a favorable Phase 1 safety profile, and a strong anti-inflammatory activity in ex-vivo studies. |
| 2025-11-10 | Genfit | Results GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025 genfit.com ↗
These preclinical findings demonstrate beneficial effects on systemic inflammation and organ failure in ACLF disease models and add to a growing body of evidence for this therapy. |
| 2023-05-09 | Genfit | Results GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week® as part of its ACLF Program genfit.com ↗
NTZ was generally well tolerated, with a favorable safety profile, in subjects with moderate and severe HI. |
| 2019-10-31 | Genfit | Results GENFIT Announces New Data to be Presented at AASLD Liver Meeting 2019 genfit.com ↗
In addition, two posters will be presented demonstrating synergistic efficacy of elafibranor in combination with nitazoxanide (NTZ) and in combination with semaglutide. |
| 2019-04-04 | Genfit | Results GENFIT announces Upcoming Presentations on NASH, PBC and Diagnostics at the European Association for the Study of the Liver (EASL) International Liver Congress 2019 genfit.com ↗
Elafibranor and nitazoxanide synergize to reduce fibrosis in a NASH model |
| 2018-03-28 | Genfit | Results GENFIT: Presentations at EASL 2018 Annual Congress Highlight Progress in NASH Diagnostics, Combination Therapies and Deep-learning Applications in Medical Imaging genfit.com ↗
In this study, NTZ complements low dose elafibranor to reduce fibrosis in a preclinical NASH model. |
| 2017-10-02 | Genfit | Results GENFIT announces its participation at the 2017 AASLD Meeting genfit.com ↗
GENFIT will present new preclinical results that show synergistic effects of nitazoxanide (drug candidate in the Company’s development pipeline) and statin combination therapy in liver fibrosis |
All press releases naming this drug 10 releases
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 118 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nitazoxanide | “Bacterial or Viral infection treatment may include: Doxycycline, Minocycline, Nitazoxanide, Hydroxychloroquine, Rifampin, Dapsone, Azithromycin, Tetracycline, Benzathine...” NCT05894954 ↗110“patients will receive LOAD therapy comprising of levofloxacin (250 mg with breakfast), omeprazole (40 mg before breakfast), nitazoxanide (Alina) (500 mg twice daily with meals)...” NCT06050824 ↗ “Group3: (110) participants received Levofloxacin quadruple regimen (LOAD) in the form of nitazoxanide 500 mg bid, levofloxacin 250 mg QD, omeprazole 40 mg QD, and doxycycline...” NCT04039412 ↗ “Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole” NCT02366884 ↗ “Naïve patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days” NCT05184491 ↗ “Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers” NCT07110441 ↗ “Moxifloxacin, omeprazole sodium bicarbonate, nitazoxanide, doxycyclin” NCT03491995 ↗ “nitazoxanide at a dosage of 7.5 mg / kg every 12 hours for 3 days” NCT05648422 ↗ “Ribavirin/Nitazoxanide (RBV/NTZ) administered” NCT04563208 ↗ “Nitazoxanide 500 mg tablets BID” NCT06101420 ↗ “Drug: Nitazoxanide” NCT05157269 ↗ |
| Known as | Alina | “nitazoxanide (Alina) (500 mg twice daily with meals)” NCT06050824 ↗ |
| Known as | Alinia | “Alinia (nitazoxanide)” NCT00302640 ↗ |
| Known as | G1090N | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07110441 ↗ |
| Known as | Netazox | “ciclezonide (Alvesco® 160 µg ) / nitazoxanide (Netazox® 500 mg)” NCT04920838 ↗ |
| Known as | Nitazoxanida | ChEMBL registry synonym — accepted as the source's own label CHEMBL1401 ↗ |
| Known as | NSC-697855 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1401 ↗ |
| Known as | NSC-760057 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1401 ↗ |
| Known as | NTX | “Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19)” NCT04463264 ↗ |
| Known as | NTZ | “We conducted a National Institute of Health-sponsored multicenter, prospective, randomized, double-blind study of nitazoxanide (NTZ) for the treatment of NoV-infected adult...” PMID 42177030 ↗ May 202623“Nitazoxanide (NTZ) plus pegylated interferon and ribavirin (Peg-IFN/RBV) improved the sustained virological response (SVR) achieved with Peg-IFN/RBV in hepatitis C virus...” PMID 26640956 ↗ Dec 2015 “Nitazoxanide (NTZ), an oral thiazolide anti-infectious agent, was safe, well tolerated and effective in achieving sustained viral response in patients with chronic HCV genotype 4.” NCT01074203 ↗ “This research is being done to determine if Nitazoxanide (NTZ) will cause a significant decrease in the number of M. tuberculosis bacteria in sputum after 14 days of treatment.” NCT02684240 ↗ “Randomized controlled study of a novel triple nitazoxanide (NTZ)-containing therapeutic regimen versus the traditional regimen for eradication of Helicobacter pylori infection.” PMID 28524341 ↗ May 2017 “Nitazoxanide (NTZ) is a novel anti-infective medication that is licenced for use in the United States (US), including in children and infants for treating some infections.” NCT02452905 ↗ “To determine the pharmacokinetics profile of single doses of nitazoxanide (NTZ) in patients with AIDS-related cryptosporidial diarrhea.” NCT00002444 ↗ “The goal of this clinical trial is to learn if nitazoxanide (NTZ) can treat Cryptosporidium infection in children age 6-12 months.” NCT06600711 ↗ “The purpose of this study is to see if nitazoxanide (NTZ) can be used to treat AIDS patients suffering from cryptosporidiosis” NCT00002158 ↗ “Nitazoxanide (NTZ) is licensed in the USA for treatment of diarrhoea caused by Cryptosporidium parvum and Giardia lamblia.” NCT04523090 ↗ “Nitazoxanide (NTZ) is a thiazolide derivative with broad-spectrum antibacterial, antiparasitic, and antiviral properties.” NCT07808450 ↗ |
| Known as | NTZ (nitazoxanide) | “NTZ (nitazoxanide)” NCT04489381 ↗5“NTZ (nitazoxanide)” NCT04343248 ↗ “NTZ (nitazoxanide)” NCT01610245 ↗ “NTZ (nitazoxanide)” NCT04486313 ↗ “NTZ (nitazoxanide)” NCT04359680 ↗ “NTZ (nitazoxanide)” NCT03605862 ↗ |
| Known as | NTZx | “Nitazoxanide (NTZx) is a derivative of 5-nitrothiazole, synthesized in 1974 by Rosignol - Cavier.” NCT04341493 ↗ |
| Known as | PH 5776 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1401 ↗ |
| Known as | Viranitta (Nitazoxanide) | “Viranitta (Nitazoxanide)” NCT04423861 ↗ |
| Action | Inhibit | “it inhibits secretion of pro-inflammatory cytokines” NCT00130390 ↗ |
| Modality | Other / unclassified | “nitazoxanide, a thiazolide anti-infective” PMID 24852376 ↗ May 2014 |
| Route | Oral | “Days 22 - 42, Arm I and Arm II will receive oral NTZ (open-label).” NCT00001081 ↗ |